Remdesivir, hydroxychloroquine did not cut hospital stay or mortality in Covid-19 patients: WHO – world news


Gilead Sciences Inc’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.

The antiviral medication, among the first to be used as a treatment for Covid-19, was one of the drugs recently used to treat US President Donald Trump’s coronavirus infection.

The results are from WHO’s “Solidarity” trial, which evaluated the effects of four potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries.

Follow latest updates on coronavirus here

The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with Covid-19, the WHO said on Thursday.

The results of the trial are yet to be reviewed and were uploaded on the preprint server medRxiv. (https://bit.ly/3nViYIf)

Earlier this month, data from a US study of remdesivir by Gilead showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo in a trial comprising 1,062 patients.

“The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir,” Gilead told Reuters.

“We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.”

WHO chief scientist Soumya Swaminathan said on Wednesday that during the study, hydroxychloroquine and lopinavir/ritonavir were stopped in June after they proved ineffective, but other trials continued in more than 500 hospitals and 30 countries.

Click here for complete coronavirus coverage

“We’re looking at what’s next. We’re looking at monoclonal anti-bodies, we’re looking at immunomodulators and some of the newer anti-viral drugs that have been developed in the last few months,” Swaminathan said.

Remdesivir received emergency use authorization from the US Food and Drug Administration on May 1, and has since been authorized for use in several countries.

Recent Articles

Kangana Ranaut gets rape threat from Odisha lawyer, he claims account was hacked, deletes it: report – bollywood

Actor Kangana Ranaut has received a rape threat from an Odisha-based lawyer. The actor, who is currently in her hometown Manali, is yet...

Assure procurement of crops at MSP by state govt if Centre falters, demands SAD – india news

Stressing that a lot still needs to be done to secure the future of Punjab’s farmers, the Shiromani Akali Dal(SAD) on Tuesday...

Pak army chief orders probe into ‘kidnap’ of police chief to force arrest of Nawaz Sharif’s son-in-law – world news

Pakistan’s Army Chief Gen Qamar Javed Bajwa has ordered an inquiry into the kidnapping of the Sindh police chief by paramilitary Rangers Force...

Badhaai Do: Rajkummar Rao to play a cop, Bhumi Pednekar a PT teacher with national dreams in this film ‘with a big heart’ –...

Ayushmann Khurrana starrer Badhaai Ho went on to become a major hit in 2018 and also won critical acclaim. The film’s makers are...

With 54,044 new cases, India’s Covid-19 tally crosses 7.6 million-mark – india news

About 54,044 new Covid-19 infections were reported in the last 24 hours in India, taking the total tally to 7,651,107. In the same...

Related Stories